Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 25

Results For "disease"

2673 News Found

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment
Biotech | January 12, 2026

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration


Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
News | January 12, 2026

Evotec subsidiary bags Gates Foundation grant to expand global access to biologics

The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats


Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe
News | January 12, 2026

Organon strikes deal with Daiichi Sankyo to launch breakthrough cholesterol drug in Northern Europe

This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway


Diabeloop bags FDA nod for DBLG2, opens US market for automated insulin delivery
Drug Approval | January 12, 2026

Diabeloop bags FDA nod for DBLG2, opens US market for automated insulin delivery

The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market


EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies
Biotech | January 12, 2026

EpiBiologics secures $107 million in Series B to advance tissue-selective cancer therapies

The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue


Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial
Clinical Trials | January 11, 2026

Ollin Biosciences’ bispecific antibody outperforms Faricimab in head-to-head Phase 1b trial

DME is among the most challenging retinal diseases to treat and has long served as a proving ground for therapies that ultimately become first-line standard of care in retinal diseases


NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial
Clinical Trials | January 11, 2026

NRG Therapeutics doses first participants in landmark ALS & Parkinson’s trial

The mPTP plays a key role in mitochondrial dysfunction, inflammation, and neuronal death in neurodegenerative diseases


Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
Biotech | January 11, 2026

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism


Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera
News | January 11, 2026

Nxera secures exclusive APAC rights to DMD drug Vamorolone in deal with Santhera

Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories


Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy
News | January 11, 2026

Halozyme and Takeda team up to transform Crohn’s and Colitis Therapy

The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab